Download pdf - Rodney POC

Roche US Diagnostics EventIndianapolis, May 17, 2005Cotton, Point-of-Care 1

r

Diagn

ostics

1

US Point of Care Diagnostics Overview

Rod CottonVice President and General ManagerPoint of Care Diagnostics, USA

r

Diagn

ostics

2

Point of Care Testing market and Roche

Strategy and future drivers


r

Diagn

ostics

3

Point-of-Care Testing (POC): DefinitionImmediately actionable healthcare information outside central lab … from diagnosis, to monitoring, to therapy adjustment

On-site testing:

• from the hospital to the home

Tests answering urgent questions:

• acute and chronic conditions

• diagnosis and therapeutic monitoring

Specific test needs:

• fast

• Simple-to-use technology

• reliable and reproducible results

ADMIT MOVE DISCHARGE

PREVENTION CURE

Point-of-Care Testing

r

Diagn

ostics

4

Three key customer segmentsImproving clinical and economic outcomes across the continuum of care

Primary CareCompliance / Convenience

real-time therapy adjustment

Patient MonitoringCompliance /

Convenience real-time therapy adjustment

Hospital

Fast therapy adjustment

Critical Care Work Area

Defined by medical indicationsDecentralized hospital testing of selected parameters

POCT used to test whole blood samples in key locations throughout the hospital

Physician’s Office Work Area

Defined by key MD user groups• Cardiologists• Intern. Medicine Physician• General Practitioner

CLIA waived POCT systems used for patient screening, therapy and monitoring activities and decisions

Patient Self-Testing

Defined by patientEvolving treatment model (e.g. anticoagulation from clinics to the patient's home)Whole blood samples (less invasive)

POCT using the blood glucose monitoring approach

"Reactive" Care Therapy monitoring Monitoring and prevention


r

Diagn

ostics

5

Rapid market growthDriven by clinical, social and economic pressures coupled with new technologies and IT capabilities

Government/ PoliticalFocused on reducing hospital length of stay and patient treatment via out-patient care models (clinic, homecare, etc)

TechnologyMaking lab-quality tests available close to patient (MD office, patient home, ICU) and delivered by non-laboratory personnel

Social/ economic pressureIncreased patient empowerment and health consciousness Third-party payers driving improvements in compliance and overall cost healthcare reductions

Clinical/ economic outcomesFocused on enabling and quantifying value of more effective and efficient care (e.g. TGC, NICU Billirubin, PST-coag)

Decision makersPhysicians, lab directors, nurses, point of care coordinators, hospital administration, IT departments

Information TechnologyIncreased use of EMR’s and other data mgt. tools to capture all testing and associated costs throughout healthcare systemFocused on faster delivery of test results to drive faster therapeutic intervention

POCT Market Drivers

r

Diagn

ostics

6

Major segments US POCT Market2003 through 2008 (m USD)

Dynamic and growing market Select segments offering double-digit growth

Total POCT*

Dedicated Primary Care Systems (Lipids, HbA1c)

Cardiac MarkersCoagulation

Dedicated Professional Glucose Testing

Urinalysis

2003

1,685

252

111146105

61

2008

2,288 E

420

218

310

177

68

11

16

11

7

8

CAGR [%]

2

289300

Blood Gas/Electrolytes

3

* Does not include manual tests e.g. pregnancy, infectious diseases and STDSource: Boston Biomedical Consultants, EAC Study, Roche research


r

Diagn

ostics

7

Roche Point of CareBroadest decentralized testing menu

Radiometer

Nova Biomedical

Elect.Arkay / Menarini

ITC

expectedIL

Dade Behring

Cholestech

expectedBiosite

Bayer

D-DimerAxis Shield

Abaxis

Abbott

planned*Roche

UAAPTTACTPTLipids & OthersStrokeCMHbA1CbG

Meta-bolitesBGECompany

Competitive Landscape

Source: Provalis * product in Centralized Diagnostics business area; Roche major manufacture for other Diagnostic companies

r

Diagn

ostics

8

The broadest portfolioAddressing Point of Care Testing customer needs

Product Lines

Businesses

• Reflotron Systems

• OMNI Systems• IT Solutions

• CoaguChek S• Accu-Chek Glucose

• Accu-Chek Inform

• Accutrend GC(T)• Urisys 1100Cardiac Reader

ResearchMolecular

LabCentral

LabSTAT Lab HosPoC POL

PatientMon.

DiabetesMgmt.

Patient CareProfessional DiagnosticsLife ScienceMarkets

Customers

BAs RAS RMD RCD RNP (POCT) RDC

Coag. Mon.Primary CareHosp. POCHosp. Glu.

Life Science Professional Diagnostics Patient Care


r

Diagn

ostics

9

Roche 19 %

Others 81 %

Roche maintains overall share leadership Among key diagnostic manufacturers, Roche clear market leader in 2 of the 4 major POCT segments

Cardiac Markers

Coagulation

Dedicated Professional Glucose Testing

Blood Gas/ Electrolytes

Roche Abbott J&JBayerBiosite

U.S. POCT Market 20041.7 bn USD (+8 %)

Source: Boston Biomedical Consultants, EAC Study, Roche analysis

r

Diagn

ostics

10

Point of Care Testing market and Roche

Strategy and future drivers


r

Diagn

ostics

11

Strategic imperatives to succeed in U.S.Drive decentralization of testing

Innovative use of information and technology to alter clinical practice and improve economic outcomeLeverage reach and penetration through acquisitions and alliances to expand offerings

Drive testing from lab to patient self-testing (prevention – e.g. PST-Coagulation)Deliver products and services enabling individualized testing and therapy

Grow market share with innovative new solutions and movement of tests from lab closer to the patientLeverage tremendous market share, growth, distribution model, installed IT systems and other assets to expand penetration across test segments

New markets

Core business

Future growth drivers

Strengthen

Shape

Stretch

r

Diagn

ostics

12

Interim/ Off-site

Driving decentralized testingFocus investments on both short and long-term opportunities across the continuum of care

• Increase investment in stand-alone POC business

• Develop strong clinical and economic sources of data to quantify value

• Expand product portfolio tied to unmet customer needs

HomePOL/Clinic

Hospital POCLab


r

Diagn

ostics

13

Historically, 3 separate businesses focused on products

Today, 1 business focused on key disease and treatment segments

HospitalPoint

of Care(HPOC)

Near Patient Testing(NPT)

Point of Care

Diagnostics

Roche Point-of-Care DiagnosticsGlobally aligned and focused on growth

DCHGHospital bGStripsMetersLancets

NPTCoag (strips/meters)UA/Primary CareCardiacElecsys/Integra

HPOCBGEInstrumentsReagents

DiseasesDiabetesCardiacCardiovascularCancerMetabolic

Treatment SegmentsPoint of Care MonitoringAcute Diagnostics Intensive CareAmbulatory Care

Diabetes Care

Hospital Group

(DCHG)

r

Diagn

ostics

14

Best-in-Class: Our advantage We will use our strong leadership position in POC Glucose and Coagulation Monitoring to drive future growth

AssetsPeople• Highest rated POC sales and service team• Passion for the Point-of-Care opportunityLeadership• History of POC share leadership• Broadest POC portfolio offering• Long-standing POC customer relationshipsPortfolio• History of technology innovation• R&D resources to maintain strong portfolioStructure• Globally aligned and focusedReach/ Distribution• Most widely contracted with National GPO’s• Most widely contracted in distribution


r

Diagn

ostics

15

Market leading portfolio and assetsOur lead in reach, innovation, reputation and performance today …

Diabetes---------

BloodGlucose

Intensive Care---------------

Blood GasElectrolyte

Cardiovascular---------------CoagulationMonitoring

Cardiac---------CardiacMarkers

Accu-Chek™Inform System

Omni-S SystemCoagu-Chek™System

Cardiac Reader™System

• Hospital share leader• #1 product• #1 sales force• #1 service• #1 GPO reach• #1 Connectivity

• Configurable system• Superior IT solutions• Innovative features• Remote QC mgt.

• 90% POL share• #1 product• Largest sales force• #1 service• Complete coag

monitoring portfolio

• 1st cardiac rapid assay• Only company with POC and

lab cardiac markers• Novel expandable technology(Myoglobin, TnT)

Strategic Leverage Drive Growth

r

Diagn

ostics

16

Diabetes---------

BloodGlucose

Intensive Care---------------

Blood GasElectrolyte

Cardiovascular---------------CoagulationMonitoring

Cardiac---------CardiacMarkers

Wireless RFTesting System

Next GenerationBGE System

Coagu-Chek™System

Cardiac Reader™System

Note: Above illustrations are for illustrative purpose only and are not be interpreted to represent current or future products

Ensuring future growth Products in development. Our innovation to ensure leading position and products tomorrow …


r

Diagn

ostics

17

Strategic imperatives

Imperatives Actions

Drive decentralization of testing from lab to patient

• Invest in health economics to provide evidence of better patient and economic outcomes

• Drive adoption of care standards across the POC testing spectrum

Obtain expanded reimbursement for patient coagulation self-monitoring

• Obtain PST specific CPT Codes

• Secure expanded indication coverage

Leverage strong Hospital position (blood glucose, IT connectivity) to grow BGE and CVDbusinesses

• Expand Hospital blood glucose

• Increase OMNI S penetration

• Launch NT-proBNP on cardiac reader